Table 1 Different types of vaccine in clinical trials against COVID-19
A. The efficacies of WHO-approved COVID-19 vaccines | ||||||
|---|---|---|---|---|---|---|
Vaccine name | Brand name | Manufacturer | Platform | Doses administered* | Dose regimens | Vaccine efficacy% (95% CI) |
BNT162b2 | Comirnaty | Pfizer-BioNTech | mRNA | 1,785,619,896 | 2 doses (21Ā days apart) | 94.6% [124] |
mRNA-1273 | Spikevax | Moderna | mRNA | 542,622,974 | 2 doses (28Ā days apart) | 94.1% [125] |
AZD1222 | Vaxzevria | AstraZeneca-Oxford | Viral vector | 200,591,659 | 2 doses (28Ā days apart) | 66.7% 55.1% (2 dosesā<ā6Ā weeks apart) 81.3% (2 dosesā>ā12Ā weeks apart) [44] |
Covishield | Serum Institute of India | Viral vector | N.D | 2 doses (4ā8Ā weeks apart) | ā~ā90% [127] | |
Ad26.COV2.S | Janssen COVID-19 Vaccine | Johnson & Johnson | Viral vector | 67,448,407 | 1 dose | 66% [126] |
BBIBP-CorV | Covilo | Sinopharm | Inactivated virus | 73,451,148 | 2 doses (21Ā days apart) | 79% [232] |
COVID-19 Vaccine | CoronaVac | Sinovac Biotech | Inactivated virus | 61,179,382 | 2 doses (14Ā days apart) | 50.4% (Brazil), 67% (Chile), 65% (Indonesia), 78% (Brazil), 84% (Turkey) Sinovac/CoronaVac COVID-19 vaccine |
BBV152 | Covaxin | Bharat Biotech | Viral vector | N.D | 2 doses (28Ā days apart) | 81% [129] |
NVX-CoV2373 | Nuvaxoid | Novavax | Protein subunit | 751,181 | 2 doses (21Ā days apart) | 89.7% [61] |
Covovax | Serum Institute of India | Protein subunit | N.D | 2 doses (21Ā days apart) | 90.4% (USA) 89.7% (UK and Mexico) COVOVAX (seruminstitute.com) | |
B. COVID-19 vaccines in Phase III trial against different variants | ||||
|---|---|---|---|---|
Vaccine name | Manufacturer | Types/Targets | Country performing Clinical trial | Trial ID |
mRNA-1273.213 | Moderna | N1-Methyl-pseudouridine (N1mĪØ) synthetic mRNA / Omicron | USA | NCT04927065 |
BNT162b2s01 | Pfizer-BioNTech | N1mĪØ synthetic mRNA / Beta | Argentina, Brazil, Germany, South Africa, Turkey, and USA | NCT04368728 |
ARCT-154 | Arcturus therapeutic | Self-amplifying mRNA / Alpha, Beta, Gamma and Delta | Viet Nam | NCT05012943 |
mRNA-1273.529 | Moderna | N1mĪØ synthetic mRNA / Omicron | United Kingdom and Northern Ireland | NCT05249829 |
AZD2816 | AstraZeneca-Oxford | AZD2816 (ChAdOx1-vectored vaccine)/ Beta | Brazil, United Kingdom, and Northern Ireland | NCT04973449 |